Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,147

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
PONV
Interventions
DRUG

APD421

DRUG

Placebo

Trial Locations (25)

11794

Stony Brook Medicine, Stony Brook

12208

Albany Medical Center Hospital, Albany

25030

University Hospital, Besançon

27157

Wake Forest University School of Medicine, Winston-Salem

27710

Duke University Medical Center, Durham

33136

Jackson Memorial Hospital, Miami

35033

Philipps University, Marburg

35660

Helen Keller Hospital, Sheffield

43210

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

53127

Universitätsklinikum Bonn, Bonn

55131

Universitätsmedizin Mainz, Mainz

66160

University of Kansas Medical Center, Kansas City

67063

Klinikum Ludwigshafen, Ludwigshafen

68051

Centre Hospitalier de Mulhouse, Mulhouse

69495

Centre Hospitalier Lyon-Sud, Lyon

77004

Victory Medical Center Houston, Houston

77024

Memorial Hermann-Memorial City Hospital, Houston

77401

First Street Surgical Center, Bellaire

94143

UCSF School of Medicine, San Francisco

02115

Brigham and Women's Hospital, Boston

Unknown

Hopital Foch, Paris

CHU de Hautepierre, Strasbourg

University Hospitals of Würzburg, Würzburg

08280

HELIOS Klinikum Aue, Aue

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Acacia Pharma Ltd

INDUSTRY